Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) insider Taylor Sandison sold 924 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $11.64, for a total value of $10,755.36. Following the sale, the insider now owns 23,067 shares in the company, valued at $268,499.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Cidara Therapeutics Trading Up 5.2 %
CDTX stock opened at $11.94 on Friday. Cidara Therapeutics, Inc. has a 1 year low of $10.00 and a 1 year high of $24.40. The company has a fifty day simple moving average of $12.17 and a 200 day simple moving average of $13.24. The firm has a market cap of $84.06 million, a PE ratio of -1.55 and a beta of 1.04.
Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($2.05) earnings per share for the quarter, topping the consensus estimate of ($3.94) by $1.89. Cidara Therapeutics had a negative return on equity of 109.89% and a negative net margin of 289.05%. The firm had revenue of $0.30 million during the quarter. As a group, analysts forecast that Cidara Therapeutics, Inc. will post -12.06 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
View Our Latest Report on CDTX
Institutional Inflows and Outflows
An institutional investor recently raised its position in Cidara Therapeutics stock. Tocqueville Asset Management L.P. raised its position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX – Free Report) by 71.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 163,000 shares of the biotechnology company’s stock after acquiring an additional 68,000 shares during the period. Tocqueville Asset Management L.P. owned approximately 3.57% of Cidara Therapeutics worth $150,000 as of its most recent SEC filing. 35.82% of the stock is owned by institutional investors.
About Cidara Therapeutics
Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
See Also
- Five stocks we like better than Cidara Therapeutics
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- Differences Between Momentum Investing and Long Term Investing
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- What Is WallStreetBets and What Stocks Are They Targeting?
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.